. 2021 Jan 4;25(2):198–206. doi: 10.1007/s10995-020-03106-y

Table 1.

Inclusion criteria for hepatitis C virus (HCV), syphilis, and 2019 coronavirus disease (COVID-19) in the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET)

	Hepatitis C	Syphilis	COVID-19
Inclusion based on maternal testing	(1) Pregnant women who are HCV RNA+ during pregnancy, or prior to pregnancy without evidence of treatment or clearance and; (2) The infants or children < 3 years of age born of that pregnancy, regardless of laboratory evidence of hepatitis C infection in the child	(1) Pregnant women who meet Council of State and Territorial Epidemiologists (CSTE) case definition^a for syphilis at any point during pregnancy and; (2) The infants or children < 3 years of age born of that pregnancy, regardless of laboratory or clinical evidence of congenital syphilis in the child	(1) Pregnant women who meet the CSTE laboratory criteria for confirmed SARS-CoV-2 infection^c at any point during pregnancy and; (2) The neonates born of that pregnancy, regardless of laboratory evidence of SARS-CoV-2 in the neonate
Inclusion based on infant/child’s testing	(1) Infants or children < 3 years of age who meet the CSTE case definition for perinatal hepatitis C, and; (2)Their birth mothers, regardless of laboratory evidence of maternal HCV infection	(1) Stillbirths, infants or children < 3 years of age who meet the probable or confirmed CSTE case definitions for congenital syphilis or syphilitic stillbirth^b and; (2) Their birth mothers regardless of laboratory evidence of maternal syphilis infection	Not applicable
Pregnancy completion or birth date	On or after January 1, 2018	On or after January 1, 2018	On or after January 1, 2020

Hepatitis C

Syphilis

COVID-19

Inclusion based on maternal testing

(1) Pregnant women who are HCV RNA+ during pregnancy, or prior to pregnancy without evidence of treatment or clearance and;

(2) The infants or children < 3 years of age born of that pregnancy, regardless of laboratory evidence of hepatitis C infection in the child

(1) Pregnant women who meet Council of State and Territorial Epidemiologists (CSTE) case definition^a for syphilis at any point during pregnancy and;

(2) The infants or children < 3 years of age born of that pregnancy, regardless of laboratory or clinical evidence of congenital syphilis in the child

(1) Pregnant women who meet the CSTE laboratory criteria for confirmed SARS-CoV-2 infection^c at any point during pregnancy and;

(2) The neonates born of that pregnancy, regardless of laboratory evidence of SARS-CoV-2 in the neonate

Inclusion based on infant/child’s testing

(1) Infants or children < 3 years of age who meet the CSTE case definition for perinatal hepatitis C, and;

(2)Their birth mothers, regardless of laboratory evidence of maternal HCV infection

(1) Stillbirths, infants or children < 3 years of age who meet the probable or confirmed CSTE case definitions for congenital syphilis or syphilitic stillbirth^b and;

(2) Their birth mothers regardless of laboratory evidence of maternal syphilis infection

Not applicable

Pregnancy completion or birth date

On or after January 1, 2018

On or after January 1, 2020

All mother–baby pairs included must reside within a participating jurisdiction

^aThis may include persons with primary, secondary, early non-primary non-secondary syphilis and unknown duration or late syphilitic infections. https://wwwn.cdc.gov/nndss/conditions/syphilis/case-definition/2018/

^bThe CSTE case definition for congenital syphilis includes stillbirths and infants born to mothers with untreated or inadequately treated syphilis and infants with laboratory evidence of congenital syphilis (direct detection of Treponema pallidum or a reactive nontreponemal syphilis test) as well as clinical or radiographic findings or cerebral spinal fluid analysis consistent with congenital syphilis. https://wwwn.cdc.gov/nndss/conditions/syphilis/case-definition/2018/

^cThe CSTE interim case definition for laboratory confirmed SARS-CoV-2 infection includes persons with detection of SARS-CoV-2 ribonucleic acid (RNA) in a clinical specimen using a molecular amplification detection test. https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/